Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1452P - Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center

Date

16 Sep 2021

Session

ePoster Display

Topics

End-of-Life Care;  Clinical Research

Tumour Site

Presenters

Kaissa Ouali

Citation

Annals of Oncology (2021) 32 (suppl_5): S1076-S1083. 10.1016/annonc/annonc679

Authors

K. Ouali1, C. Mateus1, A. Laparra2, E. Pavliuc1, P. Martin Romano2, A. Sampetrean1, A. Varga2, S. Champiat2, L. Verlingue2, A. Geraud2, A. Marabelle2, A. Hollebecque2, A. Gazzah2, R. Bahleda2, S. Postel-Vinay2, V. Ribrag2, J. Soria3, F. Scotté1, C. Massard2, C. Baldini2

Author affiliations

  • 1 Palliative Care Unit, Gustave Roussy Cancer Center, 94800 - Villejuif/FR
  • 2 Drug Development Department (ditep), Gustave Roussy Cancer Center, 94800 - Villejuif/FR
  • 3 General Director, Gustave Roussy Cancer Center, 94805 - Villejuif/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1452P

Background

Early phase clinical trials usually include patients (pts) with advanced disease who have failed to standard therapies. Early palliative care (EPC) for these pts has shown to improve quality of life and even survival. Pallia 10 score (from 1 to 10) is a tool developed by the French Palliative Care Society to identify the best time to introduce palliative care.

Methods

We assessed the Pallia 10 score and other prognostic factors (age, ECOG, Royal Marsden Hospital (RMH) score, LDH and albumin levels, number (nb) of prior systemic treatments and metastatic sites) in pts enrolled in phase I trials (P1CT) prospectively during 2 periods of time (cohort 1 (C1) and 2 (C2)). A double-blind assessment of the Pallia 10 score was done during 15 days by a member of the palliative care unit in C2. A Pallia 10 > 3 motivated a dedicated palliative care consultation.

Results

From 01/07/2018 to 01/11/2018 (C1) and from 01/12/2020 to 16/04/2021 (C2), a total of 85 pts were assessed in C1 and 302 in C2. Gastro-intestinal (23%), hematological (14%) and lung (11%) cancer were the most frequent tumor types. Pallia 10 score and prognostic factors were similar between both cohorts (Table). On C1 and C2, 12% and 4% of pts had a dedicated palliative consultation with median time of referral of 18 and 2 months (m) after the P1CT onset (p=0.003), with a median Pallia 10 score of 1.5 and 2 (p=0.65), respectively. Overall, 75% and 76% of pts in C1 and C2 were still alive beyond 3m after discontinuation of the P1CT (p=0.91), followed by at least one subsequent treatment in 56% and 54% of pts. In C2, assessment of Pallia 10 score was significantly different between palliative care physician (median 5, range 3-8), phase I physician (median 1, range 1 -6) and phase I nurse (median 3, range 1-8) (p<0.001). Table: 1452P

Cohort 1 (C1), median (range) Cohort 2 (C2), median (range) p
Age 61 (28-83) 60 (19-93) 0.36
Prior lines of therapy 3 (1-9) 3 (0-20) 0.14
Pallia 10 1 (1-5) 1 (1-8) 0.06
ECOG 1 (0-2) 1 (0-2) 0.85
RMH score 1 (0-3) 1 (0-3) 0.53
LDH level 197 (106-1318) 224 (102-2644) 0.37
Albumin level 40 (30-48) 44 (29-52) <0.001
Nb of metastatic sites 1 (0-4) 2 (0-5) <0.001

Conclusions

Only a few patients included in P1CT were referred to the palliative care unit. Median Pallia 10 score was low when assessed by the phase I physician which suggests the need for a better tool to implement EPC in clinical practice and trials.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Gustave Roussy Cancer Center.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.